Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1980 1
1981 3
1983 2
1984 3
1985 2
1986 4
1987 4
1988 3
1989 7
1990 8
1991 4
1993 1
1994 6
1995 4
1996 2
1997 9
1998 15
1999 13
2000 15
2001 18
2002 30
2003 36
2004 22
2005 27
2006 43
2007 57
2008 61
2009 100
2010 99
2011 115
2012 130
2013 171
2014 206
2015 219
2016 203
2017 246
2018 250
2019 242
2020 288
2021 332
2022 410
2023 426
2024 147

Text availability

Article attribute

Article type

Publication date

Search Results

3,545 results

Results by year

Filters applied: . Clear all
Page 1
Transcriptional and epigenetic decoding of the microglial aging process.
Li X, Li Y, Jin Y, Zhang Y, Wu J, Xu Z, Huang Y, Cai L, Gao S, Liu T, Zeng F, Wang Y, Wang W, Yuan TF, Tian H, Shu Y, Guo F, Lu W, Mao Y, Mei X, Rao Y, Peng B. Li X, et al. Among authors: shu y. Nat Aging. 2023 Oct;3(10):1288-1311. doi: 10.1038/s43587-023-00479-x. Epub 2023 Sep 11. Nat Aging. 2023. PMID: 37697166 Free PMC article.
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Xu J, et al. Among authors: shu y. JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918. JAMA. 2023. PMID: 38051328 Clinical Trial.
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH. Xu J, et al. Among authors: shu y. Lancet Oncol. 2023 May;24(5):483-495. doi: 10.1016/S1470-2045(23)00108-0. Epub 2023 Apr 17. Lancet Oncol. 2023. PMID: 37080222 Clinical Trial.
Multi-omics characterization of silent and productive HPV integration in cervical cancer.
Fan J, Fu Y, Peng W, Li X, Shen Y, Guo E, Lu F, Zhou S, Liu S, Yang B, Qin X, Hu D, Xiao R, Li X, Yang S, Yuan C, Shu Y, Huang H, Wan T, Pi Y, Wang S, Chen W, Wang H, Zhong L, Yuan L, Wen B, Kong B, Mills GB, Zou D, Xia B, Song K, Chen G, Ma D, Sun C. Fan J, et al. Among authors: shu y. Cell Genom. 2023 Jan 11;3(1):100211. doi: 10.1016/j.xgen.2022.100211. eCollection 2023 Jan 11. Cell Genom. 2023. PMID: 36777180 Free PMC article.
Intestinal activating transcription factor 4 regulates stress-related behavioral alterations via paraventricular thalamus in male mice.
Yuan F, Zhou Z, Wu S, Jiao F, Chen L, Fang L, Yin H, Hu X, Jiang X, Liu K, Xiao F, Jiang H, Chen S, Liu Z, Shu Y, Guo F. Yuan F, et al. Among authors: shu y. Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2215590120. doi: 10.1073/pnas.2215590120. Epub 2023 May 1. Proc Natl Acad Sci U S A. 2023. PMID: 37126693 Free PMC article.
AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial.
Lv J, Wang H, Cheng X, Chen Y, Wang D, Zhang L, Cao Q, Tang H, Hu S, Gao K, Xun M, Wang J, Wang Z, Zhu B, Cui C, Gao Z, Guo L, Yu S, Jiang L, Yin Y, Zhang J, Chen B, Wang W, Chai R, Chen ZY, Li H, Shu Y. Lv J, et al. Among authors: shu y. Lancet. 2024 Jan 24:S0140-6736(23)02874-X. doi: 10.1016/S0140-6736(23)02874-X. Online ahead of print. Lancet. 2024. PMID: 38280389
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Tai Y, Ma X, Shi W; CameL Study Group. Zhou C, et al. Among authors: shu y. J Thorac Oncol. 2023 May;18(5):628-639. doi: 10.1016/j.jtho.2022.12.017. Epub 2023 Jan 13. J Thorac Oncol. 2023. PMID: 36646210 Clinical Trial.
3,545 results